Missouri Roundup Cancer Lawsuits After the Supreme Court’s Preemption Ruling — What Survives, What’s Dead, and What to Do Right Now
If you used Roundup and later heard the words “non-Hodgkin lymphoma” from a doctor — and now you are reading about a Supreme Court decision that you fear just killed your case — we need you to read this page before you make a single decision. You are probably scared, probably angry, and probably being told by someone on the other side that your claim is over. We are here to tell you what the ruling actually says, what it does not say, which theories of liability may still be alive, and why the clock on your rights is still running even while the news makes it sound like everything is finished.
We are Attorney911 — The Manginello Law Firm, PLLC. Our trial team takes toxic tort and product liability cases in Missouri, working with local counsel where required, and we have spent our careers inside the machinery of mass tort litigation, corporate defendant structures, insurance valuation, and the exact kind of federal preemption doctrine the Supreme Court just wielded. What follows is not a press release. It is the honest, complete legal analysis we would give you across a kitchen table if you were sitting in front of us at two in the morning with a folder of medical records and a knot in your stomach.
What the Supreme Court Actually Decided
On June 25, 2026, the United States Supreme Court issued a 7-2 decision holding that the Federal Insecticide, Fungicide, and Rodenticide Act — FIFRA, the federal law that governs the registration, labeling, sale, and use of pesticides in this country — expressly preempts state-level failure-to-warn claims alleging that Bayer’s Monsanto failed to warn of cancer risks from its herbicide Roundup and its active ingredient glyphosate. Justice Brett Kavanaugh wrote for the majority. Justice Ketanji Brown Jackson dissented, joined by Justice Neil Gorsuch.
The underlying case came from Missouri. A jury in a Missouri state court awarded more than $1 million in compensatory damages to a plaintiff who said his cancer was caused by repeated exposure to glyphosate. A Missouri appellate court affirmed that judgment. The Supreme Court reversed and remanded — meaning the $1 million verdict is going back to the lower courts, where it now faces dismissal on preemption grounds.
The majority’s reasoning rests on a specific chain of logic: FIFRA demands uniformity in pesticide labeling. Its express preemption clause bars states from imposing labeling requirements that are “in addition to” or “different from” federal labeling requirements. The Environmental Protection Agency has registered glyphosate as eligible for use and has determined that it is “not likely to be carcinogenic to humans” — and has not required a cancer warning label on Roundup. Therefore, the majority held, any state tort law that would require Monsanto to add a cancer warning that the EPA did not require is imposing a labeling requirement “in addition to” or “different from” the federal one — and is preempted.
“With respect to pesticide labels, FIFRA demands ‘[u]niformity’ and expressly preempts state labeling requirements that are ‘in addition to’ or ‘different from’ federal labeling requirements. And as a matter of law, state tort law may not impose labeling requirements ‘in addition to’ or ‘different from’ federal requirements imposed under FIFRA.”
That is the majority’s holding in its own words. It is narrow in one sense — it addresses only failure-to-warn claims — and sweeping in another, because failure-to-warn was the primary theory of recovery in the vast majority of the estimated 100,000-plus Roundup lawsuits filed against Bayer since it acquired Monsanto in 2018.
Bayer celebrated the ruling publicly, calling it “good for science, farmers, and industries that depend on regulatory clarity for innovation” and stating that the ruling “should result in the dismissal of current warning-based claims and bar future failure-to-warn claims.” The company’s shares rose immediately after the decision. That market reaction tells you exactly what the financial world thinks this ruling is worth to Bayer: a dramatic reduction in litigation exposure.
But “should result in the dismissal of current warning-based claims” is not the same as “all Roundup cases are dead.” And that distinction is where your future begins.
What This Ruling Kills: Failure-to-Warn Claims Are Now Preempted
Let us be direct about what the ruling does. If your Roundup cancer case — pending or planned — rests solely on the theory that Monsanto failed to warn you that glyphosate could cause cancer, that theory is now preempted by federal law in every state, including Missouri. The reasoning is specific: because the EPA considered the cancer question and decided no warning was required, state courts cannot impose a duty to warn that contradicts the federal agency’s determination.
This affects three categories of cases immediately:
Pending failure-to-warn verdicts on appeal. The Durnell verdict from Missouri — more than $1 million, affirmed by the Missouri appellate court — is being reversed and remanded. On remand, the trial court will enter judgment for Monsanto on the failure-to-warn claim. Other pending appeals involving failure-to-warn verdicts face the same fate.
Pending failure-to-warn cases not yet at verdict. If your case is sitting in the Roundup multidistrict litigation (MDL-2741, before Judge Vince Chhabria in the Northern District of California, which as of mid-2026 had approximately 3,909 actions pending) or in state court and your only theory is failure to warn, Bayer’s lawyers will file motions to dismiss on preemption grounds. Those motions now have the weight of a Supreme Court decision behind them and will be difficult to defeat on the failure-to-warn theory alone.
Future failure-to-warn claims. If you have not yet filed and your case would have been pleaded as a failure-to-warn claim, you cannot file that claim and expect it to survive. The door is closed on that specific theory.
This is a significant blow. Failure to warn was the backbone of the Roundup litigation. It was the theory that produced the early verdicts — some in the tens of millions — that drove Bayer’s approximately $10 billion settlement reserve and forced the company to the negotiating table. That theory is now gone, and Bayer knows it. Their public statement about “containing” the litigation signals an intent to harden their settlement posture on every remaining case.
But — and this is the word that matters — failure to warn is not the only theory of liability in product law. And the Supreme Court’s ruling, by its own terms, addresses only labeling requirements. It does not reach every claim a plaintiff can bring against a pesticide manufacturer.
What May Still Survive: Alternative Theories of Liability
Here is where the analysis gets granular, and where the difference between a lawyer who understands preemption doctrine and one who simply reads headlines becomes the difference between a dismissed case and a viable one.
Design defect. A claim that Roundup is inherently dangerous by design — that the product itself, regardless of its label, is unreasonably dangerous — may not be a “labeling requirement” under FIFRA’s preemption clause. FIFRA’s express preemption bars state requirements for “labeling or packaging” that are “in addition to or different from” federal requirements. A design defect claim challenges the product’s formulation, not its label. To pursue this theory, a plaintiff would need to prove that the glyphosate formulation in Roundup is unreasonably dangerous in its design and that a safer alternative formulation existed. This is a harder case to build than a failure-to-warn claim — it requires expert testimony on alternative design, risk-utility analysis, and product-specific testing — but it is a fundamentally different legal theory that does not automatically fall within the four corners of the majority’s preemption reasoning.
Negligent testing and research. Claims alleging that Monsanto failed to conduct adequate safety testing, or worse, that it manipulated research findings and regulatory submissions, may not constitute “labeling requirements” under FIFRA’s preemption clause. This theory targets the company’s conduct in the laboratory and in its communications with regulators — not what it printed on the bottle. Discovery from prior Roundup cases produced internal Monsanto documents that plaintiffs alleged showed ghostwriting of scientific literature, strategic manipulation of regulatory submissions, and concerted efforts to shape the scientific narrative around glyphosate safety. If those documents support a claim that Monsanto’s research practices were negligent or worse, that claim operates in a different space from the labeling requirement the Supreme Court just preempted. Whether it survives a preemption motion is not guaranteed — defense counsel will argue that any state-law duty not to mislead the EPA is implicitly preempted or that the claim is functionally a failure-to-warn claim in disguise — but the theory has a doctrinal foothold the majority opinion did not explicitly close.
Parallel claims under FIFRA’s own misbranding prohibition. This is the roadmap Justice Jackson laid out in her dissent, and it may be the most creative path forward. FIFRA itself contains a misbranding prohibition — a federal requirement that pesticide labels not be false or misleading. Justice Jackson argued that a state-law failure-to-warn claim does not impose a requirement “in addition to” FIFRA’s mandates but instead enforces FIFRA’s own key labeling requirement. Under this theory, a plaintiff is not asking the state to impose a new warning the EPA declined to require — the plaintiff is asking the state to enforce the federal requirement that the label not be misleading. If the label’s silence on cancer risk is itself misleading given what Monsanto knew, the argument goes, then the state claim parallels rather than contradicts federal law. The majority’s reasoning creates significant headwinds for this approach, but Justice Jackson’s dissent provides the analytical framework future plaintiffs will use to attempt it.
Consumer protection and unfair trade practices claims. State consumer protection statutes may provide a vehicle for claims focused on marketing deception rather than labeling requirements. If Monsanto’s marketing materials, advertising, or public statements about Roundup’s safety were deceptive in light of what the company knew, a consumer protection claim might survive where a failure-to-warn claim does not. Defense counsel will argue these claims are also preempted as “in addition to or different from” FIFRA labeling requirements, and some courts may agree. But the theory is distinct enough from a pure labeling claim to merit separate analysis.
Wrongful death and survival actions. If a plaintiff’s cancer resulted in death, wrongful death and survival claims remain available under any non-preempted theory. Missouri’s wrongful death statute allows certain family members to recover for the death of a loved one, and the survival action allows the estate to pursue the claims the decedent would have had. These are not new theories — they are procedural vehicles for the same underlying theories (design defect, negligent testing, parallel claims) discussed above. If the underlying theory survives preemption, the wrongful death vehicle follows it.
The Dissent’s Roadmap: Justice Jackson’s Parallel-Claims Theory
The dissent is not law. It does not bind lower courts. But in the hands of a skilled appellate attorney, a well-reasoned dissent can become the foundation for future litigation strategies, legislative responses, and eventually, doctrinal shifts. Justice Jackson, joined by Justice Gorsuch, wrote something every person with a Roundup claim should understand.
“Durnell’s failure-to-warn claim is not ‘in addition to or different from’ FIFRA’s mandates; it is equivalent to FIFRA’s key labeling requirement — the misbranding prohibition. In so holding, the Court departs from the near unanimous view of the many state and federal courts that have rejected this preemption argument. In my view, the majority should have joined that chorus.”
The argument is this: FIFRA already requires that pesticide labels not be false or misleading. That is a federal requirement. A state tort claim that says “the label was misleading because it omitted a known cancer risk” is not adding a new requirement — it is enforcing the same requirement the federal law already imposes. The state is not asking Monsanto to do something FIFRA does not require. The state is asking Monsanto not to do something FIFRA already prohibits — put a misleading label on a product.
The majority rejected this framing, holding that the EPA’s specific determination that no cancer warning was required meant that a state law demanding such a warning is necessarily “in addition to” federal requirements, regardless of whether the label might also be considered misleading under FIFRA’s general misbranding prohibition. But the dissent’s reasoning may find traction in future cases where the factual record is different — particularly where plaintiffs can show that Monsanto possessed information about cancer risk that it did not share with the EPA, or where the EPA’s determination was based on incomplete or manipulated data.
The killer takeaway here: the generalist reads the headline “Supreme Court kills Roundup lawsuits” and walks away. The lawyer who reads the dissent sees a roadmap for claims that may yet survive — not as easy cases, but as viable theories that require careful pleading, strong facts, and an understanding of the difference between imposing a new requirement and enforcing an existing one.
The Science Conflict: Two Agencies, Two Answers
The Supreme Court’s ruling is built on a factual foundation that is itself contested: the EPA’s determination that glyphosate is “not likely to be carcinogenic to humans.” That determination conflicts directly with the 2015 finding by the International Agency for Research on Cancer — the World Health Organization’s cancer agency — that glyphosate is “probably carcinogenic to humans.”
This is not a minor academic disagreement. IARC is the same body whose classifications drive cancer-warning labels worldwide. Its monographs are considered the gold standard of cancer hazard identification. The IARC classification was based on peer-reviewed scientific evidence, including epidemiological studies of exposed workers and laboratory evidence of genotoxicity — the ability of a substance to damage DNA.
The EPA’s contrary determination was based on its own review of the scientific record, but that review has been criticized by scientists, advocates, and members of Congress who argue the agency relied heavily on industry-submitted studies while giving less weight to independent research. Documents produced in prior Roundup litigation have been alleged to show that Monsanto engaged in a sustained campaign to influence the scientific literature, the regulatory process, and public perception of glyphosate safety — including allegations of ghostwriting scientific papers, undisclosed consulting relationships with academic researchers, and strategic timing of data submissions to regulators.
The Supreme Court did not resolve this scientific conflict. It did not weigh the evidence. It did not decide whether glyphosate causes cancer. It decided a legal question: whether federal pesticide law, as interpreted through the EPA’s regulatory determinations, preempts state tort claims about warning labels. The science of whether glyphosate actually causes non-Hodgkin lymphoma remains a question for juries and experts in cases built on non-preempted theories — and that science, including the IARC classification and the supporting epidemiological literature, remains admissible regardless of the preemption ruling.
This matters enormously. A reader who has non-Hodgkin lymphoma and years of Roundup exposure should understand: the Supreme Court did not say your cancer wasn’t caused by glyphosate. It said the federal government’s labeling regulator decided no cancer warning was needed, and that decision preempts state-law claims about the label. What caused your cancer is a separate question from what Monsanto was required to print on a bottle.
The Defendant: Bayer AG and Monsanto Company
Understanding who you are suing — and who actually holds the money — is foundational in any mass tort case. The corporate structure here is not simple.
Bayer AG is a German multinational pharmaceutical and life sciences conglomerate. In 2018, Bayer acquired Monsanto Company for approximately $63 billion. Monsanto, an American agrochemical and agricultural biotechnology corporation headquartered in Creve Coeur, Missouri (St. Louis County), was the original developer, manufacturer, and registrant of Roundup. It controlled the scientific research and the regulatory submissions to the EPA regarding glyphosate safety.
After the acquisition, Bayer inherited not just Monsanto’s business but its mounting legal liability. Since 2018, Bayer has faced an estimated 100,000-plus Roundup-related lawsuits. Before the Supreme Court’s ruling, Bayer had allocated approximately $10 billion for Roundup litigation settlement — a number that reflected the company’s assessment of its exposure under the failure-to-warn theory that has now been largely preempted.
The corporate-structure reality: Monsanto is the entity that designed, tested, manufactured, marketed, and distributed Roundup. Monsanto is the entity that submitted data to the EPA. Monsanto is the entity whose internal documents are the discovery target. Bayer is the deep-pocket parent whose balance sheet stands behind the liability. In litigation, both entities are typically named — Monsanto for its conduct, Bayer for its acquisition and assumption of liability. Potential downstream defendants include distributors, retailers, and formulators of glyphosate products, though their exposure and financial resources are substantially less than the Bayer/Monsanto parent.
The $10 billion settlement reserve tells you something important about what this ruling changes. That money was set aside to resolve failure-to-warn claims. With those claims now preempted, Bayer’s litigation exposure drops dramatically — which means the company has less incentive to settle remaining cases on favorable terms and more incentive to fight. This is not speculation; Bayer’s own public statement said the ruling “should help significantly contain the Roundup litigation.” When a defendant says it expects to “contain” litigation, it is telling its shareholders it plans to pay less. Your leverage just changed, and you need to understand how.
Missouri’s Legal Landscape: What Remains After the Ruling
The Supreme Court’s preemption ruling establishes federal law that overrides state tort law nationwide. But Missouri’s legal framework still matters for any non-preempted claims you may pursue. Here is what remains in force:
Pure comparative fault. Missouri applies pure comparative fault principles, meaning your recovery is reduced by your percentage of fault but is not barred entirely even if you were partly responsible. If a jury finds you 30 percent at fault for your own exposure (perhaps for not wearing protective equipment), your recovery is reduced by 30 percent — but you still recover the remaining 70 percent. This is more favorable than the modified comparative fault rules in many states, which bar recovery entirely if you exceed a certain fault threshold.
No statutory cap on punitive damages in product liability cases. Missouri does not impose a statutory cap on punitive damages in product liability cases. If you can demonstrate that the defendant acted with reckless disregard for safety — and the internal Monsanto documents that prior discovery produced may support such a showing — punitive damages remain available without a statutory ceiling. This is a significant advantage for cases built on non-preempted theories, particularly negligent testing or design defect claims where corporate misconduct is provable.
The Missouri venue advantage — partially neutralized. St. Louis City and St. Louis County have historically been high-volume venues for mass tort litigation against Monsanto, partly because Monsanto was headquartered in Creve Coeur, Missouri (St. Louis County) and partly because St. Louis City Circuit Court has been known for plaintiff-leaning jury pools in toxic tort cases. Several multi-million-dollar Roundup verdicts came out of Missouri courts, and those verdicts helped drive Bayer’s broader settlement strategy. The Supreme Court’s preemption ruling neutralizes the Missouri venue advantage specifically for failure-to-warn claims — those claims are preempted regardless of where they are filed. But for plaintiffs pursuing non-preempted theories (design defect, negligent testing, parallel claims), Missouri may remain a viable forum, and its favorable damages rules — pure comparative fault and uncapped punitive damages — still apply.
Missouri’s statute of limitations. Missouri’s statute of limitations for personal injury claims allows five years to file from the date the cause of action accrues. For wrongful death, Missouri allows three years. In toxic exposure cases, the discovery rule generally provides that the clock begins running when the plaintiff knew or reasonably should have known of the injury and its cause — meaning the date of your cancer diagnosis, and your discovery of the potential link to Roundup exposure, may be the starting point, not the date you first used the product. But this is a legal determination that depends on your specific facts and your state’s accrual rules, and it is not something to gamble on. The Supreme Court’s ruling does not stop the statute of limitations clock. If you have been exposed to Roundup and diagnosed with cancer but have not yet filed, the deadline continues to approach. Delay could permanently bar even non-preempted claims.
Evidence You Must Preserve — and How Fast It Disappears
Every mass tort case is built on evidence, and in the Roundup litigation, the evidence falls into two categories: evidence about you and evidence about the company. Both have clocks on them.
Your medical records. Your cancer diagnosis, pathology reports, treatment records, and the temporal relationship between your glyphosate exposure and your diagnosis — these are generally stable in the medical system. But they should be compiled immediately. If your treating physician retires, relocates, or passes away, their deposition testimony — which can be critical in establishing specific causation — may be lost. Treating physician depositions should be preserved before physician turnover occurs.
Your exposure documentation. Employment records showing occupational use of glyphosate (agricultural workers, landscapers, groundskeepers), product purchase receipts, usage logs, and witness statements establishing the dose, duration, and frequency of your Roundup exposure. These are highly perishable. Employment records may be destroyed under standard retention policies, which commonly run about seven years. Witness memories fade. Product containers and receipts get discarded. The longer you wait, the more of this proof legally disappears.
Monsanto internal corporate documents. This is the category that separates a strong case from a weak one. Prior Roundup discovery produced internal Monsanto documents — research files, internal communications, regulatory submission drafts, and evidence plaintiffs allege shows ghostwriting of scientific literature and manipulation of regulatory submissions. These documents support design defect, negligent testing, and punitive damage theories. Many are already produced in prior cases and may be accessible, but new plaintiffs must obtain them through their own discovery — which requires filing a case before the statute of limitations expires.
EPA registration files and FIFRA correspondence. The EPA’s registration file for glyphosate, the agency’s communications with Monsanto regarding cancer classification, and the regulatory history of the EPA’s safety determination — these establish what the agency knew and when. They may also support the parallel-claims theory from Justice Jackson’s dissent by showing whether Monsanto disclosed all relevant safety information to the EPA. Federal agency records are generally preserved, but FOIA requests take months. Early filing preserves access.
IARC monograph and supporting scientific literature. The 2015 IARC classification of glyphosate as “probably carcinogenic to humans” and the supporting peer-reviewed scientific literature on glyphosate carcinogenicity remain admissible regardless of the preemption ruling. Published scientific literature is permanently available and is not at risk of destruction.
Prior corporate depositions. Transcripts from Monsanto/Bayer corporate depositions of scientists, regulatory affairs personnel, and executives from prior Roundup cases may be usable in future cases. These capture institutional knowledge before corporate restructuring or employee departure. Existing transcripts are preserved in court records, but depositions not yet taken represent knowledge that could be lost to employee turnover.
The urgency here is real. The Supreme Court ruling did not pause any of these evidence clocks. Your medical records are aging. Your employment records are cycling out. Your witnesses’ memories are degrading. And the statute of limitations is running. If you have a viable non-preempted theory, every day you wait is a day the proof gets thinner.
What Your Case May Be Worth After the Ruling
We need to be honest about what the Supreme Court’s decision does to Roundup case values. This is not a moment for inflated promises.
Failure-to-warn-only claims: $0. If your case depends solely on the theory that Monsanto failed to warn of cancer risk, the claim is preempted. A court will dismiss it. This is the hard truth the ruling delivers, and we will not soften it.
The Durnell verdict: being reversed. The more-than-$1-million Missouri jury verdict that the Supreme Court just sent back to the lower court will not stand on the failure-to-warn theory. The reversal means the plaintiff’s recovery on that theory is effectively zero unless a non-preempted theory is available on remand.
Prior Roundup verdicts: mixed procedural status. Before this ruling, juries in various courts awarded damages ranging from approximately $1 million to over $75 million in combined compensatory and punitive awards. Some of those verdicts were affirmed on appeal. Others were reduced by remittitur. Others were reversed. The record was genuinely mixed even before the Supreme Court weighed in. Now, every prior failure-to-warn verdict that has not been finalized faces preemption challenges. Cases that were built solely on failure to warn are in serious jeopardy.
Non-preempted theory cases: potentially $500,000 to $5 million or more. For cases built on viable alternative theories — design defect, negligent testing, parallel claims — the value depends on the strength of the scientific causation evidence, the quality of the exposure history, the availability of internal Monsanto documents showing corporate misconduct, and the jurisdiction’s damages rules. Cases with compelling occupational exposure histories (agricultural workers, landscapers, groundskeepers with high-dose, long-term glyphosate contact), strong non-Hodgkin lymphoma diagnoses with clear temporal causation, and access to Monsanto internal documents showing research manipulation carry the highest residual value. Missouri’s lack of a punitive damages cap in product liability cases can significantly increase case value where reckless disregard for safety is demonstrable.
The settlement landscape has shifted. Bayer’s approximately $10 billion settlement reserve was built around failure-to-warn claims. With those claims preempted, Bayer has less incentive to settle remaining cases on generous terms. The company has publicly stated the ruling “should help significantly contain the Roundup litigation.” Translation: they plan to fight harder and pay less. For plaintiffs with viable non-preempted theories, this means litigation may take longer and require more resources — but it also means the cases that survive preemption motions are the ones Bayer cannot dismiss, and those cases carry real leverage because they expose the company to the exact internal documents and corporate-conduct evidence it has been fighting to keep out of courtrooms.
Past results depend on the facts of each case and do not guarantee future outcomes. What we can tell you is that the cases with the strongest residual value are the ones where the evidence of corporate misconduct — not just the failure to warn, but the testing, research, and regulatory manipulation — is strongest. Those cases are built on documents, not labels.
The Defense Playbook: What Bayer Will Do Next — and How We Counter
Bayer’s legal strategy was already sophisticated before the Supreme Court ruling. Now it has the most powerful weapon it could have asked for. Here is what the defense will do, and here is how each play is countered.
Play 1: The “Your Claim Is Preempted” Letter. Within weeks of the ruling, Bayer’s claims administrators and defense firms will send letters to plaintiffs and their counsel stating that failure-to-warn claims are now preempted and urging dismissal or withdrawal of pending cases. The letter will read as if your entire case is dead.
Counter: The letter addresses one theory — failure to warn. It does not address design defect, negligent testing, parallel claims, or consumer protection theories. If your case can be amended to plead non-preempted theories, the preemption ruling does not end it. The response is not to walk away; it is to replead, reframe, and rebuild on the theories the Supreme Court did not reach. A lawyer who reads the preemption ruling as the end of every Roundup case is a lawyer who has not read the dissent, has not analyzed the difference between labeling requirements and product design, and has not mapped the surviving theories.
Play 2: The Hardened Settlement Posture. Before the ruling, Bayer was motivated to settle because failure-to-warn verdicts were producing large awards and the company faced tens of thousands of pending claims. Now, with those claims preempted, Bayer will approach settlement negotiations from a position of strength. They will offer less. They will delay longer. They will calculate that many plaintiffs will give up rather than fight through preemption motions and repleading.
Counter: Cases with strong non-preempted theories and compelling corporate-misconduct evidence are the cases Bayer cannot easily dismiss. Those cases expose the company to discovery on its internal research practices — the documents that produced the largest verdicts and the most damaging headlines. Bayer may have “contained” the failure-to-warn litigation, but it has not contained the documents. A well-built design defect or negligent testing case keeps those documents in play, and that is leverage the company cannot ignore.
Play 3: The Motion to Dismiss on Preemption Grounds. In every pending Roundup case, Bayer will file motions to dismiss arguing that the Supreme Court’s ruling preempts not just failure-to-warn claims but any state-law claim that “functions as” a labeling requirement. They will argue that design defect claims are really failure-to-warn claims in disguise. They will argue that negligent testing claims are really labeling claims because the testing relates to what goes on the label. They will push the preemption envelope as far as the courts will let them.
Counter: The Supreme Court’s holding is specific to labeling requirements. It did not address design defect. It did not address negligent testing. It did not address parallel claims. The defense will try to expand the ruling’s reach; our job is to hold the line at what the majority actually held — and the majority held that state tort law “may not impose labeling requirements ‘in addition to’ or ‘different from’ federal requirements.” A claim about product design is not a labeling requirement. A claim about research conduct is not a labeling requirement. These are different legal animals, and the courts that hear the defense’s expanded preemption arguments will have to decide whether the Supreme Court’s labeling ruling extends to them. Some will say yes. Some will say no. That split is where the next phase of the litigation lives.
Play 4: The “EPA Said It’s Safe” Defense. Bayer will lean heavily on the EPA’s determination that glyphosate is “not likely to be carcinogenic to humans.” They will argue that the federal government’s own safety regulator considered the cancer question and answered it, and that no state court jury should be allowed to second-guess that determination.
Counter: The EPA’s determination is not the only scientific voice on glyphosate. The IARC classification — “probably carcinogenic to humans” — represents the considered judgment of the World Health Organization’s cancer agency. The EPA’s review process has been criticized for relying heavily on industry-submitted data. And the question of whether the EPA’s determination was based on complete and accurate information — or whether Monsanto’s alleged manipulation of the regulatory process affected what the agency considered — is a question that goes to the heart of the negligent testing and parallel-claims theories. The EPA said glyphosate is safe based on what it was told. What it was told — and who shaped that information — is a separate question.
Your First Steps: An Action Plan
If you have been exposed to Roundup and diagnosed with cancer — or if you have a pending Roundup claim — here is what you should do, in order.
First: Do not accept any communication from Bayer, Monsanto, or any claims administrator at face value. If you receive a letter stating your claim is preempted, do not sign anything, do not agree to anything, and do not withdraw anything. That letter addresses one legal theory, not your entire case. Call a lawyer who understands the difference before you respond.
Second: Compile your medical records now. Your cancer diagnosis, pathology reports, treatment history, and the timeline connecting your Roundup exposure to your diagnosis. If your treating physician is still practicing, schedule a consultation to discuss the potential causal link. If your physician is nearing retirement, their deposition may need to be preserved.
Third: Document your exposure history in writing. Write down every job, every season, every period of your life where you used Roundup or were exposed to it. Include the products you used, the frequency, the duration, whether you mixed or sprayed it, whether you wore protective equipment, and the names of anyone who witnessed your exposure. Memory fades; a written timeline created now is evidence that lasts.
Fourth: Preserve physical evidence. If you still have Roundup containers, product packaging, purchase receipts, or employment records documenting your exposure, secure them. Do not discard them. Photograph them. Store them safely.
Fifth: Schedule an individualized case review. You need a lawyer to assess whether your specific facts support a non-preempted theory. Not every Roundup exposure case will survive the ruling. The ones that will are the ones with strong exposure histories, clear cancer diagnoses, and access to the corporate-conduct evidence that supports design defect and negligent testing claims. An individualized assessment — not a form letter, not a website questionnaire — is how you find out where you stand.
Sixth: Understand your statute of limitations. Missouri’s personal injury statute of limitations runs five years from accrual, and the discovery rule may start the clock at diagnosis rather than exposure. But this is a legal determination that depends on your specific facts. If you have not yet filed, the clock is running. The Supreme Court ruling did not pause it. Delay could permanently bar even non-preempted claims. We cannot state this strongly enough: the worst outcome is not losing a case on the merits. The worst outcome is having a viable case that you never get to file because the deadline passed while you were deciding whether to call.
Who We Are
We are Attorney911 — The Manginello Law Firm, PLLC. We are a trial firm that takes Missouri cases, working with local counsel where required, and we bring a specific set of tools to this fight that matter now more than ever.
Ralph P. Manginello is our Managing Partner — 27-plus years licensed, admitted to practice in Texas and in federal court including the U.S. District Court for the Southern District of Texas. Ralph was a journalist before he was a lawyer, which means he knows how to read a document, find the sentence that matters, and put it in front of a jury in language they cannot forget. He has spent nearly three decades in courtrooms on catastrophic injury and wrongful death cases, and he approaches corporate defendants the way a good reporter approaches a story: follow the paper, find the truth, and make sure the people who hid it have to answer for it.
Lupe Peña is our associate attorney — 13-plus years licensed, admitted in Texas and the U.S. District Court for the Southern District of Texas. Lupe spent years inside a national insurance-defense firm before he came to our side of the table. He sat in the rooms where adjusters and their software decided how to deny, delay, and devalue claims. He knows how claim valuation works from the inside — how reserves are set, how settlement ranges are calculated, how the defense decides which cases to fight and which to settle. Now he uses that knowledge for injured clients. Lupe is fluent in Spanish and conducts full consultations in Spanish without an interpreter.
The advantage Lupe brings to a post-ruling Roundup case is specific: he knows how a defendant like Bayer recalculates its settlement posture after a major legal victory, because he used to be the person on the other side doing that recalculation. He knows that a company that says it expects to “contain” litigation is a company that has decided to fight harder and pay less — and he knows where the leverage points are that can change that calculation back.
We work on contingency. That means we do not get paid unless we win your case. Our fee is 33.33 percent before trial and 40 percent if the case goes to trial. Your first consultation is free. We have 24/7 live staff — not an answering service, but people who can take your call at any hour and start the process immediately. We serve clients in English and Spanish. Hablamos Español.
For more information about how we handle cases like these, visit our wrongful death and survival action practice page if you have lost a loved one, or contact us directly to schedule your free case review.
Frequently Asked Questions
Can I still sue Bayer or Monsanto for Roundup cancer after the Supreme Court ruling?
Yes — but not on a failure-to-warn theory. The Supreme Court’s ruling preempts state-law claims that Monsanto failed to warn of cancer risks on the product label. However, alternative theories of liability — including design defect (the product is inherently dangerous regardless of labeling), negligent testing and research (the company failed to conduct adequate safety testing or manipulated scientific findings), parallel claims under FIFRA’s own misbranding prohibition (the label was misleading, which violates federal law itself), and consumer protection claims — may survive. Whether your specific case supports any of these theories requires an individualized assessment by a lawyer who understands preemption doctrine and the difference between a labeling requirement and a product design or research conduct claim.
I have a pending Roundup lawsuit — what happens to my case now?
If your pending case is based solely on failure to warn, you should expect Bayer’s lawyers to file a motion to dismiss on preemption grounds, citing the Supreme Court’s ruling. However, your case may be amendable to add non-preempted theories if the facts support them and the statute of limitations has not expired. Do not withdraw your case or accept a settlement offer without consulting a lawyer who has analyzed the ruling’s specific holding and the alternative theories that may be available. The ruling preempts one theory — it does not automatically dismiss every Roundup case.
I was exposed to Roundup and diagnosed with Non-Hodgkin lymphoma but have not filed — is it too late?
It may not be too late, but the clock is running. Missouri’s statute of limitations for personal injury claims generally allows five years from the date the cause of action accrues, and in toxic exposure cases, the discovery rule may mean the clock starts when you knew or should have known of your injury and its cause — potentially the date of your cancer diagnosis or when you learned of the possible link to Roundup. But this is a fact-specific legal determination. The Supreme Court ruling did not pause the statute of limitations. If you have not filed, you need to speak with a lawyer immediately to determine your deadline and whether a non-preempted theory is available before that deadline passes.
What is FIFRA preemption and why does it matter for my case?
FIFRA — the Federal Insecticide, Fungicide, and Rodenticide Act — is the federal law that governs pesticide registration, labeling, sale, and use in the United States. It requires the EPA to review and approve pesticide labels before products enter commerce. FIFRA’s express preemption clause bars states from imposing labeling requirements “in addition to” or “different from” federal labeling requirements. The Supreme Court held that because the EPA determined glyphosate is safe and did not require a cancer warning, any state tort law requiring such a warning imposes a labeling requirement “in addition to” the federal one — and is therefore preempted. This matters because it means you cannot sue Monsanto in state court for failing to warn about cancer on the Roundup label. But it does not mean you cannot sue Monsanto on other theories that do not involve labeling requirements.
The EPA says glyphosate is safe, but IARC says it probably causes cancer — which is right?
They are asking slightly different questions using different methodologies, and their answers conflict. The EPA’s determination that glyphosate is “not likely to be carcinogenic to humans” was based on the agency’s own review of the scientific record. The International Agency for Research on Cancer — the World Health Organization’s cancer agency — classified glyphosate as “probably carcinogenic to humans” in 2015, based on peer-reviewed evidence including epidemiological studies of exposed workers and laboratory evidence of DNA damage. The IARC classification remains a valid, admissible scientific assessment. The Supreme Court did not resolve this scientific conflict — it ruled on a legal question about preemption, not on whether glyphosate actually causes cancer. The science of whether your specific cancer was caused by your specific exposure remains a question for experts and, potentially, a jury.
What is a design defect claim and how is it different from failure to warn?
A failure-to-warn claim says the product’s label should have told you about a danger the manufacturer knew about. A design defect claim says the product itself — its formulation, its chemical composition, the way it was built — is unreasonably dangerous, regardless of what the label says. In a design defect case, you would need to prove that the glyphosate formulation in Roundup is inherently dangerous and that a safer alternative design existed (for example, a formulation with lower glyphosate concentration, different surfactants, or alternative active ingredients that achieve the same weed-killing effect with less carcinogenic risk). This is a harder case to build than a failure-to-warn claim because it requires expert testimony on alternative design and risk-utility analysis. But it is a fundamentally different legal theory — it challenges the product, not the label — and the Supreme Court’s preemption ruling, which addressed labeling requirements, did not explicitly reach it.
Can I still get punitive damages in a Roundup case in Missouri?
Potentially, yes — if your case proceeds on a non-preempted theory and you can demonstrate that the defendant acted with reckless disregard for safety. Missouri does not impose a statutory cap on punitive damages in product liability cases. Internal Monsanto documents produced in prior Roundup discovery — including documents plaintiffs allege show ghostwriting of scientific literature, manipulation of regulatory submissions, and suppression of safety concerns — may support a punitive damages showing if your case can access them. However, punitive damages require a higher showing than ordinary negligence, and whether the available evidence supports that showing in your specific case is a determination that requires individualized legal analysis.
How long do I have to file a Roundup cancer lawsuit in Missouri?
Missouri’s statute of limitations for personal injury claims generally allows five years from the date the cause of action accrues. For wrongful death, Missouri generally allows three years. In toxic exposure cases, the discovery rule may mean the clock starts when you knew or reasonably should have known of your injury and its cause — potentially the date of diagnosis or when you learned of the possible link between your cancer and Roundup exposure. However, accrual rules are fact-specific and can be contested by the defense. The Supreme Court’s preemption ruling did not change or pause the statute of limitations. If you have not filed, the deadline is approaching regardless of the ruling. You should not assume you have plenty of time. You should speak with a lawyer who can determine your specific deadline based on your facts.
My loved one died from cancer after years of Roundup exposure — can I still file a wrongful death claim?
Potentially, yes — on a non-preempted theory. Missouri’s wrongful death statute allows certain family members (typically spouse and children first, then parents, then other statutory beneficiaries) to bring a claim for the death of a loved one. The survival action allows the estate to pursue the claims the decedent would have had. Both are procedural vehicles for the same underlying theories — if the underlying theory (design defect, negligent testing, parallel claims) survives preemption, the wrongful death and survival vehicles follow it. Missouri’s wrongful death statute of limitations generally runs three years from the date of death. If your loved one died within the last three years, the clock may still be running. If you are outside that window, you need immediate legal analysis to determine whether any exception or tolling rule applies.
Should I accept a settlement offer from Bayer right now?
Not without consulting a lawyer who has analyzed the Supreme Court ruling and its effect on your specific case. Bayer has stated publicly that the ruling “should help significantly contain the Roundup litigation” — which means the company expects to pay less and fight harder. Any settlement offer you receive in the immediate aftermath of this ruling is likely calculated with the company’s improved legal position in mind. If your case supports a non-preempted theory — particularly one backed by strong exposure evidence and access to corporate-conduct documents — your case may be worth substantially more than what Bayer is offering to settle a preempted failure-to-warn claim. A lawyer who understands preemption doctrine, the surviving theories, and the value of the internal Monsanto documents can tell you whether the offer is fair or whether you are being lowballed by a company that just received the best legal news it could have asked for.
Take the Next Step
The Supreme Court’s ruling is a serious blow to Roundup cancer litigation. We will not pretend otherwise. But it is not the end of every case, and it does not relieve Bayer of accountability for conduct that goes beyond what was printed on a label. The questions that remain — about product design, about research integrity, about whether the regulatory process was manipulated — are questions the Supreme Court did not answer and did not close off.
If you were exposed to Roundup and diagnosed with cancer, or if you lost a loved one you believe was harmed by glyphosate exposure, call us. The consultation is free. The call costs nothing. We will give you an honest, individualized assessment of where you stand after this ruling — which theories may still be available to you, what your evidence looks like, what your deadline is, and whether your case is one that can still be fought.
1-888-ATTY-911. 1-888-288-9911. Twenty-four hours a day, seven days a week. A real person answers — not a machine, not a voicemail, not an answering service. We don’t get paid unless we win your case.
The Supreme Court changed the legal landscape. It did not change the fact that people were exposed, people got sick, and a company made decisions it may have to answer for. If your case can still be built, we can help you build it. But the clock is running, and the evidence is fading. The day you call is the day the work begins.
Past results depend on the facts of each case and do not guarantee future outcomes. This page is legal information, not legal advice. Contacting the firm is free and confidential. We serve clients in English and Spanish. Hablamos Español.